A comparison of the safety of ketamine versus etomidate in rapid sequence intubation in the community hospital emergency department setting
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Background
Rapid sequence intubation (RSI) is a technique in which an induction agent and neuromuscular
blocker are administered simultaneously to quickly enable mechanical ventilation. Compared to
other methods of intubation, RSI has a higher first attempt success rate and minimizes
complications such as prolonged hypoxemia and aspiration. Etomidate has frequently been
cited as the gold standard for RSI induction. However, recent drug shortages and potential
associations with adrenal axis suppression have renewed interests in alternative induction
agents for RSI.
Ketamine can be used for induction and has also been used as an alternative agent in pediatric
patients, those undergoing trauma, or in the hemodynamically unstable. Through a
catecholamine response, ketamine can increase cardiac output, heart rate, and blood pressure
giving it a favorable hemodynamic profile. With negligible effect on the adrenal axis, ketamine
can be used as an alternative to etomidate in patients with adrenal deficiency. However, there
is some evidence to suggest that in a catecholamine depleted patient, ketamine may have the
opposite effect on them. This occurs through a negative inotropic and chronotropic effect.

• Compare the safety of ketamine versus etomidate in patients undergoing RSI in
the emergency department
• Highlight role of ketamine in RSI in a community hospital

Outcomes
Primary

It is important for clinicians to understand a drug’s safety profile and how it might affect the
patient during RSI so they can prepare accordingly. The objective of this study aims to evaluate
the safety of ketamine versus etomidate in a community hospital emergency room setting.

Methods

Primary Outcome

Objectives and Purpose

Secondary

• Composite outcome of ketamine versus etomidate
including incidence of hypertension, hypotension,
tachycardia, or hypoxia after intubation

• Percentage of successful first pass intubation
• Additional ketamine or etomidate required
• Ketamine and etomidate dose appropriateness
• Vasopressor requirements
• Witnessed aspiration during intubation

Outcome* Ketamine Etomidate
(N=100)
(N=100)

Study Design

Baseline Characteristics
Characteristics (Mean) Ketamine (N = 100) Etomidate (N=100)

Inclusion
Criteria
Exclusion
Criteria

•> 18 years old
•Ketamine or etomidate for induction during RSI
•RSI occurs in ED

•Pregnancy
•Cardiac arrest

Age (Years)

62

70

Weight (kg)

87

83

P-Value

Composite:

15.5

23.8

0.77 (0.51-1.17)

0.22

Hypertension

9

9

1.0 (0.62-1.62)

1.0

Hypotension

9

31

0.45 (0.25-0.81)

0.008

Tachycardia

33

42

0.88 (0.66-1.18)

0.39

Hypoxia

11

13

0.92 (0.58-1.45)

0.71

Secondary Outcomes
Outcomes

•Single center, retrospective chart review
•January 2017-December 2020

HR (95% CI)

Ketamine Etomidate RR/HR (95% CI) P-Value
(N=100) (N=100)

Successful 1st Pass

91

90

1.01 (0.82-1.23)

0.96

Additional Doses Given

3

0

2.0 (1.74-2.30)

< 0.0001

Dose Appropriateness

74

78

0.97 (0.79-1.21)

0.81

39

51

0.87 (0.66-1.40)

0.31

MAP (mmHg)

89

87

Vasopressor after
Intubation

SpO2

89

92

Witnessed Aspiration

8

7

1.07 (0.65-1.75)

0.80

98

Mortality

13

28

0.63 (0.40-1.01)

0.058

HR (bpm)

104

